CAJ | 학술논문

目的：观察硫唑嘌呤联合英夫利昔单抗治疗克罗恩氏病的临床疗效。方法将70例克罗恩氏病患者随机分成对照组和治疗组，每组35例。对照组给予综合治疗，治疗组在综合治疗基础上予口服硫唑嘌呤2.5mg/kg·d，并给予静脉输注英夫利昔单抗5 mg/kg，分别于患者0，2，6周及以后每隔8周予相同剂量维持，共30周。观察两组治疗前后临床症状缓解，生化指标恢复及内镜下病理改善情况。结果与对照组相比，治疗组腹胀、腹痛等临床症状缓解，生化指标ESR、CRP下降，内镜下病理改善，P＜0.05，差异具有统计学意义。结论使用硫唑嘌呤联合英夫利昔单抗可提高克罗恩氏病患者的临床治疗效果。
목적：관찰류서표령연합영부리석단항치료극라은씨병적림상료효。방법장70례극라은씨병환자수궤분성대조조화치료조，매조35례。대조조급여종합치료，치료조재종합치료기출상여구복류서표령2.5mg/kg·d，병급여정맥수주영부리석단항5 mg/kg，분별우환자0，2，6주급이후매격8주여상동제량유지，공30주。관찰량조치료전후림상증상완해，생화지표회복급내경하병리개선정황。결과여대조조상비，치료조복창、복통등림상증상완해，생화지표ESR、CRP하강，내경하병리개선，P＜0.05，차이구유통계학의의。결론사용류서표령연합영부리석단항가제고극라은씨병환자적림상치료효과。
Objective To observe the clinical effect on therapy of azathioprine combine with infliximab on patients with crohn's disease. Methods A total of 70 cases of crohn's disease were randomly divided into control group and treatment group, each group had 35 cases. The control group received combined therapy, while the treatment was treated with orally taken with 2.5 mg/kg.d and intravenous inlfiximab 5 mg/kg besides the combined therapy, respectively in patients with medication for the ifrst time and 2, 6 weeks after every 8 weeks later in the same dose, a total of 30 weeks. Compared clinical symptoms, the restore of biochemical index and the improvement of endoscopic pathology were assessed before and after treatment. Results Compared with control group, abdominal distension, abdominal pain and other clinical symptoms, biochemical index of the ESR and CRP decreased obviously, endoscopic pathological improved in treatment group, P<0.05, had difference statistically significance. Conclusion Azathioprine combine with inlfiximab can improve the clinical treatment effect of crohn's disease and the quality of life.